Biogen Inc. (0R1B.L)
USD 118.39
(2.64%)
USD 118.39
(2.64%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.29 Billion USD | -44.11% |
| 2022 | 2.32 Billion USD | -18.32% |
| 2021 | 2.84 Billion USD | -37.57% |
| 2020 | 4.55 Billion USD | -35.39% |
| 2019 | 7.04 Billion USD | 19.6% |
| 2018 | 5.88 Billion USD | 10.19% |
| 2017 | 5.34 Billion USD | 3.76% |
| 2016 | 5.15 Billion USD | 5.3% |
| 2015 | 4.89 Billion USD | 23.12% |
| 2014 | 3.97 Billion USD | 57.92% |
| 2013 | 2.51 Billion USD | 35.54% |
| 2012 | 1.85 Billion USD | 7.6% |
| 2011 | 1.72 Billion USD | 38.1% |
| 2010 | 1.24 Billion USD | -3.59% |
| 2009 | 1.29 Billion USD | 6.74% |
| 2008 | 1.21 Billion USD | 55.64% |
| 2007 | 779.77 Million USD | 77.21% |
| 2006 | 440.02 Million USD | 86.42% |
| 2005 | 236.04 Million USD | 443.67% |
| 2004 | 43.41 Million USD | 104.99% |
| 2003 | -869.66 Million USD | -393.18% |
| 2002 | 296.63 Million USD | -17.65% |
| 2001 | 360.19 Million USD | 9.7% |
| 2000 | 328.35 Million USD | 3.83% |
| 1999 | 316.25 Million USD | 65.89% |
| 1998 | 190.63 Million USD | 27.97% |
| 1997 | 148.96 Million USD | 264.86% |
| 1996 | 40.82 Million USD | 448.41% |
| 1995 | 7.44 Million USD | 490.4% |
| 1994 | -1.9 Million USD | -108.79% |
| 1993 | 21.7 Million USD | -24.13% |
| 1992 | 28.6 Million USD | 2300.0% |
| 1991 | -1.3 Million USD | -262.5% |
| 1990 | 800 Thousand USD | 108.89% |
| 1989 | -9 Million USD | 24.37% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 545.4 Million USD | 87.04% |
| 2024 Q2 | 652.4 Million USD | 19.62% |
| 2024 Q3 | 451 Million USD | -23.91% |
| 2023 Q4 | 291.6 Million USD | 306.52% |
| 2023 Q3 | -141.2 Million USD | -121.53% |
| 2023 Q1 | 526.9 Million USD | 54.93% |
| 2023 FY | 1.29 Billion USD | -44.11% |
| 2023 Q2 | 655.7 Million USD | 24.44% |
| 2022 Q2 | 973.1 Million USD | 59.34% |
| 2022 FY | 2.32 Billion USD | -18.32% |
| 2022 Q4 | 340.1 Million USD | -60.0% |
| 2022 Q3 | 850.3 Million USD | -12.62% |
| 2022 Q1 | 610.7 Million USD | 4.02% |
| 2021 Q2 | 485.7 Million USD | -50.13% |
| 2021 FY | 2.84 Billion USD | -37.57% |
| 2021 Q3 | 794 Million USD | 63.48% |
| 2021 Q4 | 587.1 Million USD | -26.06% |
| 2021 Q1 | 973.9 Million USD | 394.59% |
| 2020 FY | 4.55 Billion USD | -35.39% |
| 2020 Q3 | 1.08 Billion USD | -44.98% |
| 2020 Q1 | 1.81 Billion USD | 2.37% |
| 2020 Q2 | 1.97 Billion USD | 8.49% |
| 2020 Q4 | -330.6 Million USD | -130.43% |
| 2019 Q3 | 1.8 Billion USD | -7.65% |
| 2019 Q2 | 1.95 Billion USD | 30.16% |
| 2019 FY | 7.04 Billion USD | 19.6% |
| 2019 Q1 | 1.5 Billion USD | 4.13% |
| 2019 Q4 | 1.77 Billion USD | -1.58% |
| 2018 FY | 5.88 Billion USD | 10.19% |
| 2018 Q3 | 1.69 Billion USD | 39.93% |
| 2018 Q2 | 1.21 Billion USD | -20.95% |
| 2018 Q1 | 1.53 Billion USD | 4.7% |
| 2018 Q4 | 1.44 Billion USD | -14.99% |
| 2017 Q3 | 1.65 Billion USD | 37.72% |
| 2017 Q1 | 1.02 Billion USD | 15.58% |
| 2017 Q4 | 1.46 Billion USD | -11.35% |
| 2017 Q2 | 1.2 Billion USD | 17.21% |
| 2017 FY | 5.34 Billion USD | 3.76% |
| 2016 Q4 | 886.2 Million USD | -37.82% |
| 2016 Q1 | 1.37 Billion USD | 17.99% |
| 2016 Q2 | 1.46 Billion USD | 5.96% |
| 2016 Q3 | 1.42 Billion USD | -2.41% |
| 2016 FY | 5.15 Billion USD | 5.3% |
| 2015 FY | 4.89 Billion USD | 23.12% |
| 2015 Q4 | 1.16 Billion USD | -14.84% |
| 2015 Q3 | 1.37 Billion USD | 11.25% |
| 2015 Q2 | 1.23 Billion USD | 10.31% |
| 2015 Q1 | 1.11 Billion USD | -3.61% |
| 2014 Q1 | 671.34 Million USD | 2.04% |
| 2014 Q3 | 1.15 Billion USD | 16.57% |
| 2014 FY | 3.97 Billion USD | 57.92% |
| 2014 Q4 | 1.15 Billion USD | 0.62% |
| 2014 Q2 | 988.72 Million USD | 47.27% |
| 2013 Q3 | 684.53 Million USD | 3.32% |
| 2013 FY | 2.51 Billion USD | 35.54% |
| 2013 Q1 | 510.52 Million USD | 14.59% |
| 2013 Q2 | 662.52 Million USD | 29.77% |
| 2013 Q4 | 657.92 Million USD | -3.89% |
| 2012 Q1 | 369.37 Million USD | -9.71% |
| 2012 Q3 | 535.25 Million USD | 5.84% |
| 2012 Q4 | 445.5 Million USD | -16.77% |
| 2012 Q2 | 505.72 Million USD | 36.92% |
| 2012 FY | 1.85 Billion USD | 7.6% |
| 2011 FY | 1.72 Billion USD | 38.1% |
| 2011 Q4 | 409.1 Million USD | -16.25% |
| 2011 Q3 | 488.49 Million USD | 18.91% |
| 2011 Q2 | 410.81 Million USD | -1.31% |
| 2011 Q1 | 416.28 Million USD | 17.2% |
| 2010 Q1 | 303.68 Million USD | -20.79% |
| 2010 FY | 1.24 Billion USD | -3.59% |
| 2010 Q4 | 355.18 Million USD | 82.96% |
| 2010 Q3 | 194.13 Million USD | -50.96% |
| 2010 Q2 | 395.88 Million USD | 30.36% |
| 2009 Q4 | 383.37 Million USD | -0.21% |
| 2009 Q3 | 384.17 Million USD | 72.34% |
| 2009 FY | 1.29 Billion USD | 6.74% |
| 2009 Q1 | 304.95 Million USD | -6.16% |
| 2009 Q2 | 222.91 Million USD | -26.9% |
| 2008 FY | 1.21 Billion USD | 55.64% |
| 2008 Q1 | 246 Million USD | -6.26% |
| 2008 Q2 | 296.79 Million USD | 20.65% |
| 2008 Q3 | 345.85 Million USD | 16.53% |
| 2008 Q4 | 324.96 Million USD | -6.04% |
| 2007 FY | 779.77 Million USD | 77.21% |
| 2007 Q2 | 206.44 Million USD | 13.62% |
| 2007 Q3 | 129.21 Million USD | -37.41% |
| 2007 Q4 | 262.43 Million USD | 103.1% |
| 2007 Q1 | 181.69 Million USD | -5.23% |
| 2006 Q3 | 197.32 Million USD | 261.72% |
| 2006 Q4 | 191.71 Million USD | -2.84% |
| 2006 Q2 | -122.01 Million USD | -170.53% |
| 2006 Q1 | 172.98 Million USD | 85.41% |
| 2006 FY | 440.02 Million USD | 86.42% |
| 2005 Q4 | 93.29 Million USD | 340.82% |
| 2005 FY | 236.04 Million USD | 443.67% |
| 2005 Q2 | 46.3 Million USD | -38.49% |
| 2005 Q1 | 75.27 Million USD | 29.97% |
| 2005 Q3 | 21.16 Million USD | -54.29% |
| 2004 Q3 | 70.83 Million USD | 4918.57% |
| 2004 Q4 | 57.91 Million USD | -18.23% |
| 2004 FY | 43.41 Million USD | 104.99% |
| 2004 Q1 | -83.86 Million USD | 92.39% |
| 2004 Q2 | -1.47 Million USD | 98.25% |
| 2003 Q1 | 93.9 Million USD | 14.17% |
| 2003 Q3 | 70.86 Million USD | 4.27% |
| 2003 Q4 | -1.1 Billion USD | -1655.62% |
| 2003 Q2 | 67.96 Million USD | -27.62% |
| 2003 FY | -869.66 Million USD | -393.18% |
| 2002 Q3 | 69.08 Million USD | 32.49% |
| 2002 Q4 | 82.24 Million USD | 19.06% |
| 2002 Q2 | 52.13 Million USD | -44.04% |
| 2002 Q1 | 93.16 Million USD | 0.22% |
| 2002 FY | 296.63 Million USD | -17.65% |
| 2001 Q2 | 91.07 Million USD | 5.2% |
| 2001 Q3 | 89.58 Million USD | -1.63% |
| 2001 Q4 | 92.96 Million USD | 3.77% |
| 2001 FY | 360.19 Million USD | 9.7% |
| 2001 Q1 | 86.57 Million USD | -6.65% |
| 2000 Q1 | 84.03 Million USD | -12.14% |
| 2000 Q3 | 64.48 Million USD | -25.96% |
| 2000 Q2 | 87.09 Million USD | 3.64% |
| 2000 Q4 | 92.73 Million USD | 43.82% |
| 2000 FY | 328.35 Million USD | 3.83% |
| 1999 Q1 | 61.9 Million USD | -4.68% |
| 1999 Q3 | 84.4 Million USD | 14.05% |
| 1999 Q4 | 95.65 Million USD | 13.33% |
| 1999 FY | 316.25 Million USD | 65.89% |
| 1999 Q2 | 74 Million USD | 19.55% |
| 1998 Q2 | 41 Million USD | 12.02% |
| 1998 Q4 | 64.93 Million USD | 32.8% |
| 1998 FY | 190.63 Million USD | 27.97% |
| 1998 Q1 | 36.6 Million USD | -46.62% |
| 1998 Q3 | 48.9 Million USD | 19.27% |
| 1997 Q3 | 28.5 Million USD | 1.06% |
| 1997 FY | 148.96 Million USD | 264.86% |
| 1997 Q1 | 23.9 Million USD | -3.35% |
| 1997 Q2 | 28.2 Million USD | 17.99% |
| 1997 Q4 | 68.56 Million USD | 140.59% |
| 1996 FY | 40.82 Million USD | 448.41% |
| 1996 Q4 | 24.72 Million USD | -32.43% |
| 1996 Q3 | 36.6 Million USD | 395.16% |
| 1996 Q2 | -12.4 Million USD | -55.0% |
| 1996 Q1 | -8 Million USD | -157.37% |
| 1995 Q3 | -2.7 Million USD | 22.86% |
| 1995 Q4 | 13.94 Million USD | 616.48% |
| 1995 FY | 7.44 Million USD | 490.4% |
| 1995 Q2 | -3.5 Million USD | -288.89% |
| 1995 Q1 | -900 Thousand USD | -108.83% |
| 1994 FY | -1.9 Million USD | -108.79% |
| 1994 Q1 | 9.4 Million USD | 246.88% |
| 1994 Q2 | -3.1 Million USD | -132.98% |
| 1994 Q3 | -26.2 Million USD | -745.16% |
| 1994 Q4 | 10.19 Million USD | 138.9% |
| 1993 FY | 21.7 Million USD | -24.13% |
| 1993 Q2 | 9.1 Million USD | -3.19% |
| 1993 Q1 | 9.4 Million USD | -60.5% |
| 1993 Q4 | -6.4 Million USD | -179.01% |
| 1993 Q3 | 8.1 Million USD | -10.99% |
| 1992 FY | 28.6 Million USD | 2300.0% |
| 1992 Q3 | 8.8 Million USD | 438.46% |
| 1992 Q4 | 23.8 Million USD | 170.45% |
| 1992 Q2 | -2.6 Million USD | -36.84% |
| 1992 Q1 | -1.9 Million USD | -26.67% |
| 1991 FY | -1.3 Million USD | -262.5% |
| 1991 Q2 | 300 Thousand USD | -72.73% |
| 1991 Q4 | -1.5 Million USD | -36.36% |
| 1991 Q3 | -1.1 Million USD | -466.67% |
| 1991 Q1 | 1.1 Million USD | -21.43% |
| 1990 Q1 | 200 Thousand USD | 106.06% |
| 1990 Q4 | 1.4 Million USD | 566.67% |
| 1990 Q3 | -300 Thousand USD | 62.5% |
| 1990 Q2 | -800 Thousand USD | -500.0% |
| 1990 FY | 800 Thousand USD | 108.89% |
| 1989 Q2 | 6.9 Million USD | -14.81% |
| 1989 FY | -9 Million USD | 24.37% |
| 1989 Q1 | 8.1 Million USD | 130.11% |
| 1989 Q3 | -2.8 Million USD | -140.58% |
| 1989 Q4 | -3.3 Million USD | -17.86% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 81.093% |
| Dynavax Technologies Corporation | -37.02 Million USD | 3602.215% |
| Illumina, Inc. | -1.06 Billion USD | 221.31% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 34.406% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 381.571% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -19.27% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 584.199% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 24711.881% |
| Waters Corporation | 817.67 Million USD | -58.596% |
| Perrigo Company plc | 151.9 Million USD | -753.72% |
| uniQure N.V. | -282.87 Million USD | 558.442% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 431.25% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 1864.498% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 569.845% |
| bluebird bio, Inc. | -244.26 Million USD | 630.905% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 1167.369% |
| Imunon, Inc. | -21.03 Million USD | 6266.303% |
| Myriad Genetics, Inc. | -123.7 Million USD | 1148.343% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | -416.859% |
| Nektar Therapeutics | -137.42 Million USD | 1043.642% |
| Editas Medicine, Inc. | -169.18 Million USD | 866.516% |
| Verastem, Inc. | -92.08 Million USD | 1508.279% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 109.213% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 2976.836% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 1272.355% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 3003.262% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -566.938% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 573.276% |
| Evolus, Inc. | -49.23 Million USD | 2734.006% |
| Adicet Bio, Inc. | -152.03 Million USD | 952.945% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 1432.005% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 67.957% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 933.617% |
| FibroGen, Inc. | -281.81 Million USD | 560.16% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 3.941% |
| OPKO Health, Inc. | -157.02 Million USD | 925.877% |
| Homology Medicines, Inc. | -48.25 Million USD | 2787.39% |
| Geron Corporation | -193.94 Million USD | 768.647% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 559.573% |
| Exelixis, Inc. | 170.88 Million USD | -658.873% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 1386.163% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 2425.848% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 351.664% |
| Zoetis Inc. | 3.06 Billion USD | 57.745% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 659.387% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 2790.456% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 69.894% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 3412.134% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 466.607% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -1108.777% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -284.153% |
| Blueprint Medicines Corporation | -486.27 Million USD | 366.679% |
| Insmed Incorporated | -709.62 Million USD | 282.744% |
| TG Therapeutics, Inc. | 20.63 Million USD | -6185.077% |
| Incyte Corporation | 620.52 Million USD | -108.984% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 278.524% |